{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:53:45Z","timestamp":1792292025523,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848017008"],"award-info":[{"award-number":["848017008"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003061","name":"Erasmus Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Critically ill patients undergo extensive physiological alterations that will have impact on antibiotic pharmacokinetics. Up to 60% of intensive care unit (ICU) patients meet the pharmacodynamic targets of beta-lactam antibiotics, with only 30% in fluoroquinolones. Not reaching these targets might increase the chance of therapeutic failure, resulting in increased mortality and morbidity, and antibiotic resistance. The DOLPHIN trial was designed to demonstrate the added value of therapeutic drug monitoring (TDM) of beta-lactam and fluoroquinolones in critically ill patients in the ICU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multi-centre, randomised controlled trial (RCT) was designed to assess the efficacy and cost-effectiveness of model-based TDM of beta-lactam and fluoroquinolones. Four hundred fifty patients will be included within 24\u2009months after start of inclusion. Eligible patients will be randomly allocated to either study group: the intervention group (active TDM) or the control group (non-TDM). In the intervention group dose adjustment of the study antibiotics (cefotaxime, ceftazidime, ceftriaxone, cefuroxime, amoxicillin, amoxicillin with clavulanic acid, flucloxacillin, piperacillin with tazobactam, meropenem, and ciprofloxacin) on day 1, 3, and 5 is performed based upon TDM with a Bayesian model. The primary outcome will be ICU length of stay. Other outcomes amongst all survival, disease severity, safety, quality of life after ICU discharge, and cost effectiveness will be included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>No trial has investigated the effect of early TDM of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients. The findings from the DOLPHIN trial will possibly lead to new insights in clinical management of critically ill patients receiving antibiotics. In short, to TDM or not to TDM?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      EudraCT number:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-004677-14\/NL\">2017\u2013004677-14<\/jats:ext-link>\n                      . Sponsor protocol name: DOLPHIN. Registered 6 March 2018 . Protocol Version 6, Protocol date: 27 November 2019.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-4781-x","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T09:02:50Z","timestamp":1579251770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2158-6376","authenticated-orcid":false,"given":"A.","family":"Abdulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. M. J.","family":"Ewoldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. G. M.","family":"Hunfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. E.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. J. R.","family":"Rietdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Polinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Endeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C. P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"issue":"4","key":"4781_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00075198-200208000-00011","volume":"8","author":"AF Shorr","year":"2002","unstructured":"Shorr AF. An update on cost-effectiveness analysis in critical care. Curr Opin Crit Care. 2002;8(4):337\u201343.","journal-title":"Curr Opin Crit Care"},{"issue":"21","key":"4781_CR2","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1001\/jama.2009.1754","volume":"302","author":"JL Vincent","year":"2009","unstructured":"Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. Jama. 2009;302(21):2323\u20139.","journal-title":"Jama"},{"issue":"12","key":"4781_CR3","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1007\/s00134-016-4504-3","volume":"42","author":"SepNet Critical Care Trials G","year":"2016","unstructured":"SepNet Critical Care Trials G. Incidence of severe sepsis and septic shock in German intensive care units: the prospective, multicentre INSEP study. Intensive Care Med. 2016;42(12):1980\u20139.","journal-title":"Intensive Care Med"},{"issue":"5","key":"4781_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1097\/01.CCM.0000260960.94300.DE","volume":"35","author":"A Esteban","year":"2007","unstructured":"Esteban A, Frutos-Vivar F, Ferguson ND, Penuelas O, Lorente JA, Gordo F, et al. Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med. 2007;35(5):1284\u20139.","journal-title":"Crit Care Med"},{"issue":"2","key":"4781_CR5","doi-asserted-by":"publisher","first-page":"R42","DOI":"10.1186\/cc4854","volume":"10","author":"DA Harrison","year":"2006","unstructured":"Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC case mix Programme database. Crit Care. 2006;10(2):R42.","journal-title":"Crit Care"},{"issue":"1","key":"4781_CR6","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1186\/cc12544","volume":"17","author":"AA Udy","year":"2013","unstructured":"Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman J. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Crit Care. 2013;17(1):R35.","journal-title":"Crit Care"},{"issue":"5","key":"4781_CR7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jcrc.2013.03.003","volume":"28","author":"BO Claus","year":"2013","unstructured":"Claus BO, Hoste EA, Colpaert K, Robays H, Decruyenaere J, De Waele JJ. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care. 2013;28(5):695\u2013700.","journal-title":"J Crit Care"},{"issue":"12","key":"4781_CR8","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1007\/s00134-004-2428-9","volume":"30","author":"R Mehrotra","year":"2004","unstructured":"Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med. 2004;30(12):2145\u201356.","journal-title":"Intensive Care Med"},{"issue":"1","key":"4781_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00228-018-2565-7","volume":"75","author":"MS Camargo","year":"2019","unstructured":"Camargo MS, Mistro S, Oliveira MG, Passos LCS. Association between increased mortality rate and antibiotic dose adjustment in intensive care unit patients with renal impairment. Eur J Clin Pharmacol. 2019;75(1):119\u201326.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"4781_CR10","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","volume":"73","author":"JW Mouton","year":"2017","unstructured":"Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J. MIC-based dose adjustment: facts and fables. J Antimicrob Chemother. 2017;73(3):564\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"4781_CR11","volume-title":"General Consultation on \u201cConsiderations in the numerical estimation of epidemiological cutoff (ECOFF) values\u201d","author":"EUCAST","year":"2018","unstructured":"EUCAST. General Consultation on \u201cConsiderations in the numerical estimation of epidemiological cutoff (ECOFF) values\u201d. 2018 [updated 22-03-2018. Available from: http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Consultation\/2018\/ECOFF_procedure_2018_General_Consultation_20180531.pdf."},{"issue":"1","key":"4781_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","volume":"26","author":"WA Craig","year":"1998","unstructured":"Craig WA. Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1\u201310 quiz 1-2.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4781_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1055\/s-0034-1398490","volume":"36","author":"MH Abdul-Aziz","year":"2015","unstructured":"Abdul-Aziz MH, Lipman J, Mouton JW, Hope WW, Roberts JA. Applying pharmacokinetic\/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med. 2015;36(1):136\u201353.","journal-title":"Semin Respir Crit Care Med"},{"issue":"4","key":"4781_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","volume":"31","author":"PS McKinnon","year":"2008","unstructured":"McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31(4):345\u201351.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"4781_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ijantimicag.2014.12.017","volume":"45","author":"A Huttner","year":"2015","unstructured":"Huttner A, Von Dach E, Renzoni A, Huttner BD, Affaticati M, Pagani L, et al. Augmented renal clearance, low beta-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study. Int J Antimicrob Agents. 2015;45(4):385\u201392.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"4781_CR16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072\u201383.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4781_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jcrc.2007.11.011","volume":"23","author":"AR van Zanten","year":"2008","unstructured":"van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care. 2008;23(3):422\u201330.","journal-title":"J Crit Care"},{"key":"4781_CR18","volume-title":"Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients","author":"A Abdulla","year":"2019","unstructured":"Abdulla A, Rogouti O, Hunfeld NGM, Endeman H, Dijkstra A, van Gelder T, et al. Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients. Manuscript submitted. 2019."},{"issue":"1","key":"4781_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04337.x","volume":"75","author":"M Haeseker","year":"2013","unstructured":"Haeseker M, Stolk L, Nieman F, Hoebe C, Neef C, Bruggeman C, et al. The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. Br J Clin Pharmacol. 2013;75(1):180\u20135.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4781_CR20","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ijantimicag.2008.05.019","volume":"32","author":"J-M Conil","year":"2008","unstructured":"Conil J-M, Georges B, de Lussy A, Khachman D, Seguin T, Ruiz S, et al. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Int J Antimicrob Agents. 2008;32(6):505\u201310.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"4781_CR21","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1053\/j.jvca.2016.03.145","volume":"30","author":"PJ Yu","year":"2016","unstructured":"Yu PJ, Cassiere HA, Fishbein J, Esposito RA, Hartman AR. Outcomes of patients with prolonged intensive care unit length of stay after cardiac surgery. J Cardiothorac Vasc Anesth. 2016;30(6):1550\u20134.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"5","key":"4781_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/intqhc\/14.5.403","volume":"14","author":"Y Arabi","year":"2002","unstructured":"Arabi Y, Venkatesh S, Haddad S, Al Shimemeri A, Al MS. A prospective study of prolonged stay in the intensive care unit: predictors and impact on resource utilization. Int J Qual Health Care. 2002;14(5):403\u201310.","journal-title":"Int J Qual Health Care"},{"issue":"10","key":"4781_CR23","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/jac\/dkx209","volume":"72","author":"S Imani","year":"2017","unstructured":"Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. Too much of a good thing: a retrospective study of beta-lactam concentration-toxicity relationships. J Antimicrob Chemother. 2017;72(10):2891\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"4781_CR24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.phrs.2018.07.005","volume":"134","author":"F de Velde","year":"2018","unstructured":"de Velde F, Mouton JW, de Winter BCM, van Gelder T, Koch BCP. Clinical applications of population pharmacokinetic models of antibiotics: challenges and perspectives. Pharmacol Res. 2018;134:280\u20138.","journal-title":"Pharmacol Res"},{"issue":"2","key":"4781_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","volume":"39","author":"RP Dellinger","year":"2013","unstructured":"Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis campaign: international guidelines for Management of Severe Sepsis and Septic Shock, 2012. Intensive Care Med. 2013;39(2):165\u2013228.","journal-title":"Intensive Care Med"},{"issue":"2","key":"4781_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijantimicag.2009.10.008","volume":"35","author":"JA Roberts","year":"2010","unstructured":"Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents. 2010;35(2):156\u201363.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"4781_CR27","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00134-017-4780-6","volume":"43","author":"T T\u00e4ngd\u00e9n","year":"2017","unstructured":"T\u00e4ngd\u00e9n T, Ramos Mart\u00edn V, Felton TW, Nielsen EI, Marchand S, Br\u00fcggemann RJ, et al. The role of infection models and PK\/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017;43(7):1021\u201332.","journal-title":"Intensive Care Med"},{"issue":"9","key":"4781_CR28","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1086\/656623","volume":"51","author":"KA Bauer","year":"2010","unstructured":"Bauer KA, West JE, Balada-Llasat J-M, Pancholi P, Stevenson KB, Goff DA. An antimicrobial stewardship Program's impact. Clin Infect Dis. 2010;51(9):1074\u201380.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"4781_CR29","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1097\/CCM.0000000000001140","volume":"43","author":"D Zhang","year":"2015","unstructured":"Zhang D, Micek ST, Kollef MH. Time to appropriate antibiotic therapy is an independent determinant of postinfection ICU and hospital lengths of stay in patients with sepsis. Crit Care Med. 2015;43(10):2133\u201340.","journal-title":"Crit Care Med"},{"key":"4781_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jchromb.2017.06.014","volume":"1060","author":"A Abdulla","year":"2017","unstructured":"Abdulla A, Bahmany S, Wijma RA, van der Nagel BCH, Koch BCP. Simultaneous determination of nine \u03b2-lactam antibiotics in human plasma by an ultrafast hydrophilic-interaction chromatography\u2013tandem mass spectrometry. J Chromatogr B. 2017;1060:138\u201343.","journal-title":"J Chromatogr B"},{"key":"4781_CR31","volume-title":"Clinical breakpoints and dosing of antibiotics: EUCAST","author":"EUCAST","year":"2019","unstructured":"EUCAST. Clinical breakpoints and dosing of antibiotics: EUCAST; 2019 [updated 08\u201301\u20132019. Available from: http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"issue":"1","key":"4781_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13054-017-1609-1","volume":"21","author":"H-J de Grooth","year":"2017","unstructured":"de Grooth H-J, Geenen IL, Girbes AR, Vincent J-L, Parienti J-J, Oudemans-van Straaten HM. SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care. 2017;21(1):38.","journal-title":"Crit Care"},{"issue":"10","key":"4781_CR33","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","volume":"42","author":"MH Abdul-Aziz","year":"2016","unstructured":"Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, Rai V, Wong KK, Hasan MS, et al. Beta-lactam infusion in severe Sepsis (BLISS): a prospective, two-Centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016;42(10):1535\u201345.","journal-title":"Intensive Care Med"},{"issue":"1","key":"4781_CR34","first-page":"63","volume":"21","author":"J Lipman","year":"2019","unstructured":"Lipman J, Brett SJ, De Waele JJ, Cotta MO, Davis JS, Finfer S, et al. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent beta-lactam antibiotic infusion in critically ill patients with sepsis: BLING III. Crit Care Resusc. 2019;21(1):63\u20138.","journal-title":"Crit Care Resusc"},{"issue":"1","key":"4781_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"R Guilhaumou","year":"2019","unstructured":"Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Societe Francaise de Pharmacologie et Therapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Societe Francaise d'Anesthesie et reanimation-SFAR). Crit Care. 2019;23(1):104.","journal-title":"Crit Care"},{"issue":"6","key":"4781_CR36","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/QCO.0000000000000494","volume":"31","author":"AJ Heffernan","year":"2018","unstructured":"Heffernan AJ, Sime FB, Taccone FS, Roberts JA. How to optimize antibiotic pharmacokinetic\/pharmacodynamics for gram-negative infections in critically ill patients. Curr Opin Infect Dis. 2018;31(6):555\u201365.","journal-title":"Curr Opin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4781-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-4781-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4781-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T19:06:31Z","timestamp":1610737591000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-4781-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4781"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-4781-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"28 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial was approved by the Medical Ethics Committee of the Erasmus Medical Centre in Rotterdam, the Netherlands (registration number MEC-2017-568). This ethical approval covers all study sites. Every significant amendment to the protocol will have to be approved by the local medical ethics committee. The local feasibility was tested by the medical ethics committee and board of directors of all study sites included in the trial. Written informed consent will be taken from the patients or the legal representative before being recruited into the trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}